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Introduction
This is a summary of the 2017 updated Dutch psoriasis guide-
line, based on the Dutch Society of Dermatology and Venere-
ology guideline on the treatment of psoriasis (2011),1,2 the
European Dermatology Forum (EDF) guideline on the treat-
ment of psoriasis (2015)3 and newer literature. The focus is
mainly on patients with moderate-to-severe psoriasis, which is
the minority of the total patient population. Topical therapies
and phototherapies are outside the scope of this update, but
remain important treatment options.
We provide sections per drug and patient group, aiming for
a useful manual for daily clinical practice, including recom-
mendations for screening and monitoring. In the section on
treatment decisions in psoriasis we address the most important
aspects of therapeutic decision making. To support dermatolo-
gists in making treatment decisions, we provide a concise
physician decision aid for the biologics and the small molecule
inhibitor apremilast (Table S1; see Supporting Information).
The following sections have been updated: systemic therapy
(methotrexate, fumarates, adalimumab, etanercept, infliximab,
ustekinumab), treatment for paediatric patients, serum con-
centration and antibody formation in biologics, and quality of
life. There are newly added sections on treatment decisions in
psoriasis, secukinumab, apremilast, combination therapy, pso-
riatic arthritis, biosimilars, and pregnancy and biologics. The
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section on paediatric patients provides guidance on topical
therapy and phototherapy in addition to conventional systemic
therapy and biologics. We have only included agents that were
available in the Netherlands at the start of the update in 2015,
meaning that ixekizumab, brodalumab, guselkumab, certolizu-
mab and risankizumab are not included. The sections on reti-
noids and ciclosporin were not updated; only when strictly
necessary minor changes were made, which are clearly indi-
cated in the text. For more detailed information, we refer
readers to the full guideline.4
Guideline development
The systematic literature search used for the EDF guideline on
the treatment of psoriasis5 was updated until July 2015. For
topics that were not covered in the EDF guideline a separate
systematic literature search was conducted in MEDLINE,
Embase and CENTRAL in July 2015. Details of the search
strategies are presented in the full guideline.4 The guideline
working group consisted of dermatologists and a rheumatolo-
gist, a dermatology nurse and a patient with psoriasis as repre-
sentatives of their national societies. This working group
formulated research questions and outcome measures for the
updated and new sections. The outcomes are presented in
Table 1. Induction or short-term therapy was defined as
16 weeks, long-term therapy as 24 weeks.
Articles were screened for inclusion and exclusion criteria
based on the title and abstract by two researchers indepen-
dently. The full texts were analysed by members of the work-
ing group. The risk of bias of the included studies was
assessed using the Cochrane Risk of Bias Assessment Tool.6
Data analysis was performed using Review Manager. We
added data from the new literature to the EDF analysis, and
shared this updated version with the EDF psoriasis guideline
working group. The quality of evidence was evaluated using
the Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) system for grading evidence7 using
GRADEpro GDT online software8 for most sections.
Recommendations
Recommendations were formulated by the working group
based on the level of evidence according to GRADE. To indi-
cate the strength of the recommendation the formulation in
Table 2 was used.
Summary of the guideline
Treatment decisions in psoriasis (2017)
The majority of patients with psoriasis have mild disease in
which topical therapy is sufficient to suppress the lesions. If nec-
essary, different forms of phototherapy and/or conventional
systemic therapy are considered with or without topical agents.
With the arrival of biologics, treatment options have increased
and the effects of treatments have improved drastically.
It can be challenging to choose a suitable therapy for an
individual patient. However, we expect that if the treatment is
in line with patients’ expectations, preferences and lifestyle,
adherence to the treatment and increased treatment satisfaction
are more likely.9 We recommend that treatment decisions
should therefore be made by patients and physicians together
Table 1 Assessed outcomes and assigned rating of importance
Outcome Importance
Efficacy
Induction or short-term therapy (16 weeks)
PASI 75 response Crucial
PASI 90 response Important
Reduction in mean PASI/final PASI score Important
Clearance (i.e. PGA 0, PASI 100, ‘clear’) Important
PGA 0/1 (e.g. ‘clear/almost clear’) Crucial
Long-term therapy (24 weeks)
PASI 75 response Crucial
PASI 90 response Important
Reduction in mean PASI/final PASI score Important
Clearance (e.g. PGA 0, PASI 100, ‘clear’) Important
PGA 0/1 (e.g. ‘clear/almost clear’) Crucial
Safety
Withdrawal due to adverse event Crucial
Number of patients with at least one adverse
event
Important
Number of patients with at least one serious
adverse event (as listed in study)
Crucial
Patient reported
Response in DLQI score ≤ 5 Important
Reduction in mean DLQI Important
Others
Time until onset of action: time until 25% of
patients achieve a PASI 75 response
Important
Time until onset of action: time until a 25%
reduction in the mean baseline PASI is achieved
Important
Time to relapse (after discontinuation of
treatment)
Important
Relapse rate at a given point X in the publication Important
PASI, Psoriasis Area and Severity Index; PASI 75, 75% improve-
ment in PASI; PGA, Physician’s Global Assessment; DQLI, Derma-
tology Quality of Life Index.
Table 2 Wording for recommendations
Strength Wording
Strong recommendation for the use
of an intervention
Intervention X is
recommended
Weak recommendation for the use
of an intervention
Intervention X is suggested
No recommendation No recommendation can
be made
Weak recommendation against the
use of an intervention
Intervention X is not
suggested
Strong recommendation against the
use of an intervention
Intervention X is not
recommended
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(‘shared decision making’). In our opinion it is important that
all agents remain equally accessible and available. A preferred
policy for rigid application of one drug is undesirable.
We suggest that the following aspects should be addressed
in order to choose the best-suiting therapy. These aspects are
also summarized in Figure 1.
• Patient aspects. Patient-related factors that should be consid-
ered in treatment decisions are (but not limited to) age,
sex, comedication, comorbidity, previous agents, stage of
life, (wish for) pregnancy, profession, hobbies and (psy-
chosocial) burden of disease.
• Disease aspects. The type of psoriasis, severity and localization
of the lesions, joint and/or nail involvement should be
taken into consideration.
• Treatment aspects. This includes short-term and long-term
treatment effects and safety, route of administration, fre-
quency of administration, burden of treatment, adverse
events and antibody formation.
• Predictors for treatment success. Ideally, we should include pre-
dictors for treatment success or failure in the therapeutic
decision. Research is ongoing but an applicable set of such
predictors is not yet defined.
• Therapeutic recommendations. Considering the high costs of bio-
logical therapy, cost-efficient prescription is necessary.
Topical therapy, phototherapy and conventional systemic
therapy remain important in the treatment of psoriasis and
are effective in a substantial proportion of patients. Even
though some biologics can be prescribed as a first-line sys-
temic treatment (according to the label text) when a
patient is eligible for systemic therapy, we have formu-
lated the following recommendation: we recommend only
prescribing biologics and/or apremilast in cases of
inadequate response to, or intolerance/contraindications
for phototherapy and one or more conventional sys-
temic agents as mentioned in this guideline. In the case of
high disease activity, contraindications and/or adverse
prognostic factors then deviation from this advice is
possible.
• Costs. There are ways to help keep the costs of biological
therapy manageable. Studies on the effects of dose reduc-
tion, interval extension and treatment optimization (by
combining biologics with other conventional systemic
agents) are important and currently ongoing. Physicians
should take the extra costs into account when considering
increasing a dose or interval shortening of biologics. Also,
prescription of biosimilars might lower the costs, and this
is discussed further in the section on biosimilars. Although
important, costs should never be the only leading factor in
the treatment decision.
Fig 1. Flowchart for treatment decisions in psoriasis.
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Treatment goals
After carefully choosing a therapy, it remains important to
check regularly if the treatment still meets the requirements
and/or goals. To prevent undertreatment of psoriasis, it is
recommended to adapt and follow the treatment goals as
described by Mrowietz et al.10 in daily practice (see their
Fig. 2):
• ≥ 75% improvement in the Psoriasis Area and Severity
Index (PASI 75) after induction therapy: continue treat-
ment.
• < PASI 50 improvement after induction therapy: modify
therapy.
• ≥ PASI 50 and < PASI 75 improvement after induction
therapy: continue treatment if Dermatology Life Quality
Index (DLQI) ≤ 5 and modify treatment if DLQI > 5.
In addition, patients’ satisfaction with treatment should be
taken into consideration.
To support physicians in the choice of therapy we have
developed a physician decision aid (Table S1; see Supporting
Information) combining the aspects discussed above.
Systemic therapy (2017)
See Table S2 (Supporting Information) for advice on screening
and monitoring in systemic therapy.
Methotrexate (2017)
Recommendations Methotrexate is recommended for both
induction and long-term therapy in patients with moderate-
to-severe plaque-type psoriasis (Table S3; see Supporting
Information). In case of inadequate response (according to the
treatment goals), it is recommended to increase the dose from
15 to 30 mg per week.
Table S4 details blood tests and their timing. Routine mea-
surement of procollagen III N-terminal peptide is no longer
recommended, because of the limited added value in the
detection of liver fibrosis compared with alanine transaminase
and low specificity of increased procollagen III N-terminal
peptide.11 Physicians should be alerted to other risk factors for
liver fibrosis (e.g. hepatic steatosis, metabolic syndrome) aside
from methotrexate therapy. Monitoring according to Figure 2
is recommended.
Ciclosporin (2011)
Recommendations Ciclosporin is recommended as induction ther-
apy in moderate-to-severe plaque-type psoriasis (Table S5; see
Supporting Information). Because of its fast-acting effect,
ciclosporin is particularly useful for short-term therapy and
crisis intervention. Ciclosporin may be prescribed for longer
terms (maximum of 2 years) in individual cases, but close
monitoring for signs of toxicity such as renal impairment and
hypertension is important. Table S6 (see Supporting Informa-
tion) details blood tests and their timing.
Acitretin (2011)
Recommendations Acitretin is recommended for induction ther-
apy in moderate-to-severe plaque-type psoriasis, although it
is not recommended as a first-choice monotherapy (Table S7;
see Supporting Information). In patients with a good clinical
Fig 2. Flowchart for methotrexate (MTX) therapy. ULN, upper limit of normal; ALT, alanine transaminase; ɣGT, gamma-glutamyl transferase;
DM, diabetes mellitus.
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effect at the end of induction therapy (16 weeks), mainte-
nance therapy is suggested with the lowest effective dose.
Table S8 (see Supporting Information) details blood tests and
their timing.
Women of childbearing age should not be treated with aci-
tretin because of the teratogenic characteristics of the drug.
Contraception is recommended during and up to 3 years after
treatment discontinuation (modified in 2017).
Fumarates (2017)
Recommendations Fumarates are recommended as induction and
long-term therapy for moderate-to-severe plaque-type psoria-
sis (Table S9; see Supporting Information). In general, the
long-term safety profile of fumarates is favourable, but the
evidence is relatively limited.12–14 Acetylsalicylic acid (e.g.
80 mg) is suggested to treat flushing as an undesired side-
effect of therapy.15
The incidence of progressive multifocal leucoencephalopathy
during treatment with fumarates is unknown, but seems related
to prolonged periods of lymphocytopenia. In addition to moni-
toring for lymphocytopenia (Table S10; see Supporting Infor-
mation), we recommend being alert for neurological
symptoms during fumarate therapy and referring a patient to a
neurologist if needed. Table S11 (see Supporting Information)
details recommended dosing.
Apremilast (2017)
Recommendations Apremilast is suggested as induction therapy
and long-term therapy in moderate-to-severe plaque-type pso-
riasis (Table S12; see Supporting Information). Long-term
safety data are relatively scarce.
In patients with severe renal impairment (creatinine clear-
ance < 30 mL min1) 30 mg once daily is recommended.
Table S13 and Table S14 (see Supporting Information) detail
blood tests and dosing for apremilast, respectively.
Adalimumab (2017)
Recommendations Adalimumab is recommended as induction ther-
apy and long-term therapy in moderate-to-severe plaque-type
psoriasis (Table S15; see Supporting Information). Increasing
the dose of adalimumab from 40 mg per 2 weeks to 40 mg per
week is suggested for patients with an insufficient response to
adalimumab 40 mg per 2 weeks. This dosage increase is
according to the label change (November 2015). Table S16 (see
Supporting Information) details blood tests for all biologics.
Etanercept (2017)
Recommendations Etanercept is recommended as induction therapy
and long-term therapy in moderate-to-severe plaque-type pso-
riasis (Table S17; see Supporting Information). A starting dose
of 50 mg twice weekly is suggested, over a dose of 50 mg
once weekly. Undesired effects of long-term treatment are
similar to induction therapy. A maintenance dose of 50 mg
twice weekly is suggested over a dose of 50 mg once weekly.
Infliximab (2017)
Recommendations Infliximab is recommended as induction therapy
for chronic plaque-type psoriasis in week 0, 2 and 6
(Table S18; see Supporting Information). Infliximab is recom-
mended as maintenance therapy every 8 weeks (with at least
4 weeks between two administrations).
Secukinumab (2017)
Recommendations Secukinumab is recommended as induction
therapy in chronic plaque-type psoriasis (Table S19; see Sup-
porting Information). A dose of 300 mg is recommended
over a dose of 150 mg in induction therapy. Secukinumab is
suggested for maintenance therapy. Long-term safety data are
limited.
Ustekinumab (2017)
Recommendations Ustekinumab is recommended as induction
therapy in chronic plaque-type psoriasis (Table S20; see Sup-
porting Information). Ustekinumab 45 mg is suggested in
patients ≤ 100 kg. Ustekinumab 90 mg is suggested in
patients > 100 kg. Ustekinumab is recommended as a mainte-
nance therapy for at least 5 years. The long-term safety profile
of ustekinumab over a period of 5 years appears not to be evi-
dently different from that for 1 year in additional literature.
Combination therapy (2017)
Prescription of systemic combination therapy is currently off-
label. Patients should be informed about this off-label use and
possible side-effects. Therapy should be started only after care-
ful weighing of benefits and risks tailored to the individual
patient.16
Recommendations Etanercept in combination with methotrexate
is suggested as induction and maintenance therapy of chronic
plaque-type psoriasis. Etanercept in combination with acitretin
is suggested as induction and maintenance treatment of
chronic plaque-type psoriasis (based on one maintenance
study).16
Biologics or methotrexate in combination with ultraviolet B
is not recommended as a maintenance treatment in patients
with chronic plaque-type psoriasis because of a lack of data
on safety.16
Treatment with adalimumab, infliximab, ustekinumab or
secukinumab in combination with methotrexate is suggested
in treatment-resistant psoriasis.
Serum trough level and detection of antidrug antibodies
(2017)
The serum trough level of a biologic depends on many fac-
tors, among which are dose and dose frequency, treatment
adherence, disease activity, antibody formation and
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comedication with immunosuppressants. The extent to which
the presence or absence of antibodies and the drug serum
concentrations correlate to the clinical response depends on
the type of biologic and needs further exploration.
At the moment a correlation between trough level concen-
tration and clinical effect has only been demonstrated for adal-
imumab.17 A therapeutic algorithm based on serum trough
levels has potential to improve adalimumab therapy, but no
prospective studies have been performed yet.
Recommendations It may be useful to determine adalimumab
serum trough levels before altering the frequency of adminis-
tration or stop/switch therapy. A low serum trough level con-
centration can be caused by antidrug antibodies. The optimal
serum trough concentration has been established for adali-
mumab (351–700 mg L1).18 Measurement of only antidrug
antibodies provides limited information.
Biosimilars (2017)
Currently approved biosimilars are available for infliximab
(RemsimaTM, Celltrion Healthcare, Budapest, Hungary;
InflectraTM, Hospira, Maidenhead, U.K.; and Flixabi, Biogen
Idec, Cambridge, MA, U.S.A.) and for etanercept (Benepali,
Biogen, Cambridge, MA, U.S.A.; and Erelzi, Novartis Pharma
AG, Stein, Switzerland).
Recommendations There are no major objections to starting a
registered biosimilar for patients eligible for biological ther-
apy. It is recommended that patients be included in a registry
to monitor efficacy and safety. Substitution of a biologic with
a biosimilar in patients who are responding well is not recom-
mended, but the decision to switch to a biosimilar in these
patients is reserved for the physician and patient. Physicians
should take into consideration that long-term safety data for
biosimilars are limited.
It is possible for patients who discontinue a biological ther-
apy (for example for more than 6 months) to restart with a
biosimilar. In the case of switching to a biosimilar, it is rec-
ommended to administer the first dose of the biosimilar when
the old reference product was supposed to be re-administered
and not before, as the old drug may still be partially present
in the body, which makes it impossible to attribute side-
effects to either of the two drugs. These recommendations are
in line with the Dutch national guideline on biosimilars.19
Psoriatic arthritis (2017)
The following paragraph is based on the Dutch guideline for
axial spondyloarthritis (2014)20 and international European
League Against Rheumatism (2015)21 and Group for Research
and Assessment of Psoriasis and Psoriatic Arthritis guidelines
(2016).22
Recommendations As a result of the increased risk in patients
with psoriasis, it is recommended that physicians be alert for
signs of psoriatic arthritis (PsA): spontaneous persistent pain,
swelling or stiffness of one or more joints and nearby
ligaments and tendons, or chronic back pain present for at
least 3 months before the age of 45 years. It is recommended
that patients with psoriasis be referred to a rheumatologist if
there is a suspicion of peripheral arthritis, dactylitis, enthesitis
or if they have experienced daily chronic back pain for at least
3 months before the age of 45 years. Cooperation with and
consultation with a rheumatologist is strongly recommended
not just for diagnostics but also for treatment of PsA. Routine
additional testing before referral to a rheumatologist is not
recommended. Nonsteroidal anti-inflammatory drugs are rec-
ommended as the first step in the treatment of PsA.
Tuberculosis screening (2017)
Recommendations A Dutch multidisciplinary guideline is currently
being developed on screening for tuberculosis before the start
of immunosuppressive therapy. For now, we recommend
screening all patients before starting biological therapy. In line
with the EDF guideline and the current national statement on
screening for latent tuberculosis infection we recommend
undertaking the following:3,23
• Medical history including tuberculosis history.
• Physical examination.
• Chest X-ray.
• Tuberculin skin test (Mantoux) and interferon gamma
release assay.
Vaccination (2017)
The use of live vaccines is discouraged during immunosup-
pressive therapy (Table 3).24 Exceptions can be made in
Table 3 Advice on duration between stopping immunosuppressant
and administration of live vaccine in adult patients
Advice on duration Time
Between stopping immunosuppressant and administration of live
vaccine
Methotrexate 3 months (based on half-life 1 month
may be sufficient; nevertheless wait
3 months if possible)24,26
Ciclosporin 3 months24,26,59,60
Fumarates No known contraindication (no data)
Apremilast No data, 3 months is advised
Etanercept 3 months (no data, based on expert
opinion and half-life of the drug)
Adalimumab 3 months24,26,59,60
Infliximab 3 months, for yellow fever vaccine
minimum of 6 months24,26,59,60
Ustekinumab 3 months24,26,59,60
Secukinumab No data, 3 months is advised
Ixekizumab No data, 3 months is advised
Between live vaccine and (re)starting immunosuppressive
therapy
All systemic agents Minimum of 4 weeks3,24–26
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specific circumstances (e.g. for mumps, measles, rubella and
varicella in specific cases), in consultation with a vaccine spe-
cialist. In patients with immunosuppressive therapy, it is rec-
ommended that (live) vaccines, except for the yearly influenza
vaccine, be given in consultation with a specialist in the field
of vaccinations/immunology/travel diseases; additional mea-
sures may be necessary (e.g. titre control in common vaccines,
live vaccine measures). Vaccines should preferably be adminis-
tered before starting immunosuppressants.
It is advised to wait for at least 4 weeks after a live vaccine
to (re)start immunosuppressive medication.3,24–26 Beware of
live vaccinations in newborns of mothers treated with
immunosuppressive therapy, as it might be necessary to post-
pone live vaccines.
Pregnancy (2017)
The time a woman should wait to conceive after stopping bio-
logical therapy depends on the half-life of the drug.
Recommendations Our recommendations are summarized in
Table 4. We suggest starting or continuing biological therapy
in pregnant women and women planning a pregnancy only if
the benefits outweigh the risks of treatment. In such cases
there is a slight preference for etanercept given the short half-
life and the relatively low transplacental transfer to the fetus.
It is recommended that biologics be stopped, especially the
IgG immunoglobulins such as infliximab and adalimumab,
before the end of the second trimester to minimize the risk of
neonatal immunosuppression.
Pregnancy in a woman treated with a biologic requires a
multidisciplinary approach, therefore counselling by a gynae-
cologist is recommended. It might be necessary to postpone
administration of live vaccinations and bacillus Calmette–
Guerin vaccinations in neonates exposed to biologics in utero,
especially in the third trimester. Pregnant patients treated with
biologics should preferably be treated in an academic hospital.
Data on pregnancy should preferably be kept in a registry.
Paediatric psoriasis (2017)
This section is based on van Geel et al. (2015),27 supple-
mented with more recent literature.
Topical therapy
Recommendations Topical corticosteroids are useful in the treat-
ment of paediatric psoriasis, with class II–III potency recom-
mended. Dependent on the disease severity, a combination
with vitamin D3 analogues is recommended. Since the combi-
nation calcipotriol/betamethasone dipropionate contains a
class III corticosteroid, it is recommended that this treatment
be prescribed only for short-term therapy (a maximum of
4 weeks) if possible.
For maintenance therapy vitamin D3 analogues (especially
calcipotriol) are first choice, given the effect and favourable
side-effects. If necessary a class II corticosteroid can be added.
If, in recalcitrant psoriasis, a combination with class III ster-
oid is necessary, intermittent use is strongly recommended.
Tacrolimus (003% or 01%) ointment is suggested to treat
resistant psoriasis of the face and intertriginous folds. If treat-
ment with (a combination of) topical corticosteroids or vita-
min D3 analogues fails in paediatric psoriasis (and adherence
is ensured), dithranol in a day care setting should be seriously
considered before phototherapy or systemic therapy is started.
Phototherapy
Recommendations It is recommended that narrowband-ultraviolet B
phototherapy is only used to a limited extent in paediatric
Table 4 Advice on contraceptiona
Drug
Methotrexate Women: during therapy and at least 3–6 months
after stop (no consensus in literature)
Men: during therapy and at least 3–6 months
after stop (no consensus in literature)
Acitretin Women: during therapy and at least 3 years after
stopb
Double contraceptive measures are advised
because of very teratogenic character
Men: no specific preventive measures
Ciclosporin Women: during therapy
Men: no specific preventive measures
Fumarates Women: during therapy and at least 2 weeks
after stop
Men: no specific preventive measures
Apremilast Women: during therapy and at least 28 days
after stop
Men: during therapy and at least 28 days after
stop (lack of data)
Adalimumab Women: during therapy and at least 5 months
after stop
Men: no specific preventive measures (limited
data)
Etanercept Women: during therapy and at least 3 weeks
after stop. When treatment is unavoidable and
benefits outweigh the risks, treatment with
etanercept during pregnancy can be considered
Men: no specific preventive measures (limited
data)
Infliximab Women: during therapy and at least 6 months
after stop
Men: no specific preventive measures (limited
data)
Secukinumab Women: during therapy and at least 20 weeks
after stop
Men: during therapy (lack of data)
Ustekinumab Women: during therapy and at least 15 weeks
after stop
Men: during therapy (lack of data)
aBased on drug-specific summary of product characteristics and
Nast, Garritsen, Yiu, and Grunewald.3,61–63 bModified in 2017
based on changed recommendations in summary of product
characteristics.
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psoriasis. It should be used cautiously, particularly in young
(age < 12 years) and in fair-skinned children. It is the opinion
of the guideline working group, that children should not be
treated with home ultraviolet B. Given the proven carcinogenic
effect, psoralen–ultraviolet A therapy is contraindicated in pae-
diatric psoriasis.
Systemic therapy
Recommendations The effect of antibiotics in children with guttate
psoriasis remains controversial. In the case of a suspect medi-
cal history of tonsillitis and positive throat culture, treatment
with antibiotics can be considered.
Acitretin is suggested for paediatric psoriasis (including pus-
tular or erythrodermic forms). Treatment in adolescent
women is advised against because of the teratogenic potential
of acitretin. Ciclosporin is recommended in exceptional situa-
tions and for short-term treatment only, given the potential
nephrotoxicity. Methotrexate is recommended in a dose range
between 02 and 04 mg kg1 weekly. Folic acid 5–10 mg
24 h after ingestion of methotrexate is recommended. If
fumarates are used for paediatric psoriasis, one should be
aware of prolonged leucocytopenia/lymphocytopenia and fol-
low the recommendations described in the section on fuma-
rates in this guideline.
Biologics
Recommendations Biologics should be administered with caution
in children with moderate-to-severe psoriasis given the uncer-
tainty about long-term safety. The working group suggests
considering the conventional systemics first.
In order to evaluate long-term safety, it is recommended
including children treated with a biologic in a (national) reg-
istry. Treatment of paediatric patients with psoriasis with bio-
logics should be the preserve of dermatologists with
experience in biological therapy, especially in children.
For instructions for use/screening/frequency of laboratory
checks of biological therapy in children please refer to the
instructions described for adults in the various sections. It is
recommended to check the vaccination status of children (ac-
cording to the national vaccination programme) before start-
ing biological therapy.
Etanercept is recommended as an induction and mainte-
nance therapy in children and adolescents with plaque-type
psoriasis from the age of 6 years who are inadequately con-
trolled with use of, or are intolerant to, other systemic agents
or phototherapy. Dosage is 08 mg kg1 (up to 50 mg per
dose) once a week.
Adalimumab is recommended as an induction therapy in
children and adolescents aged 4 years and older with plaque-
type psoriasis who have had an inadequate response to or are
inappropriate candidates for topical therapy and phototherapy.
Long-term safety data in children are not available. Dosage is
08 mg kg1 (up to 40 mg per dose) week 0, 1 and there-
after every other week.
Ustekinumab is recommended in adolescent patients with
chronic plaque-type psoriasis from the age of 12 years whose
condition is inadequately controlled with use of, or who are
intolerant to, other systemic agents or phototherapy. Long-
term safety data in children are not available. The recom-
mended dose for adolescents < 60 kg is 075 mg kg1, for
those with a weight ≥ 60 to ≤ 100 kg the dose is 45 mg and
for patients > 100 kg the dose is 90 mg. Administration is at
week 0 and 4, and every 12 weeks thereafter.
Quality of life and treatment satisfaction in psoriasis
(2017)
Quality of life
Many patients with psoriasis experience an impairment in their
quality of life, and anxiety and depression occur more fre-
quently compared with healthy individuals.28–33 Patients with
psoriasis experience limitations in physical functioning because
of itching, reduced sleep quality, fatigue and pain, and experi-
ence limitations in social functioning, including stigmatiza-
tion.34–42 Biologics, systemic agents, phototherapy and topical
therapy have a beneficial effect on patient’s quality of life.43–50
Recommendations It is recommended that attention be explicitly
paid to the impact of psoriasis on quality of life in dermato-
logical practice. Physicians are encouraged, where possible and
relevant, to determine patient’s quality of life by asking, or
with the use of standardized questionnaires such as the DLQI
or Skindex-29. Optionally, measurements of itch, pain and
loss of sleep can be performed.
As patients with psoriasis are often stigmatized, it is recom-
mended this topic be discussed.
In the case of suspicion of (serious) psychological prob-
lems, it is suggested the patient be referred to a psychologist
or psychosocial worker who can investigate this with validated
questionnaires.
Treatment satisfaction
Only about half of patients with psoriasis are satisfied with
their current treatment.51,52 Treatment satisfaction is highest
in patients treated with biologics compared with systemic
therapy, phototherapy and topical therapy.1,53–58
Recommendations It is recommended attention be paid, where
possible and relevant, to treatment satisfaction by asking
patients about their satisfaction with treatment and care. The
generic Treatment Satisfaction Questionnaire for Medication
(TSQM) can be used for this purpose. If necessary, treatment
adjustments should be made.
Discussion
This summary highlights the most important aspects of sys-
temic therapy in patients with psoriasis. The decision aid for
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systemic therapies (Table S1) can serve as a useful tool for
clinical practice, and it also clearly highlights the gaps in cur-
rent evidence. Clinical signs are described most extensively,
with the PASI and the Physician’s Global Assessment as fre-
quently reported efficacy outcome measures. However, com-
parison between studies remains challenging because of the
extensive variation in study outcomes, such as PASI 75, PASI
90, PASI 100 and change in mean PASI and also the different
time points of evaluations (e.g. 12, 16, 24, 52 weeks after
start of treatment). In addition, in other domains, such as
quality of life, different instruments are used, such as the
DLQI, Skindex-29, TSQM and visual analogue scale scores,
making comparison between studies very difficult. The devel-
opment of a core outcome set for psoriasis is recommended
by the working group, as this will increase the comparability
between studies and therefore improve the quality of the
aggregated evidence. We encourage the involvement of
patients in treatment decisions. To improve shared decision
making we are currently developing a nationwide, online
patient decision aid for psoriasis.
A limitation of the guideline is that it focuses on chronic
plaque-type psoriasis and therefore not all types of psoriasis
are discussed. Strengths are that we have included a section on
PsA, with recommendations for screening, referral indications
and treatment in collaboration with the Dutch Society of
Rheumatology and in which we strongly encourage a multi-
disciplinary treatment approach for patients with psoriatic skin
lesions and PsA. Psoriasis in children is discussed in a separate
section.
In this guideline we recommend following the European
consensus treatment goals described by Mrowietz et al.10 in
2011, but given the increased effectiveness of the newest
classes of targeted biologics, we should reconsider if these
goals are still sufficient. Is it time to raise the standards? The
present gold standard of PASI 75 may be abandoned in favour
of PASI 90 or PASI 100. Beside treatment goals, we also rec-
ommend including patient satisfaction in the decision to
adjust, stop or continue treatment. Importantly, treatment
goals for mild psoriasis are lacking, but are needed to stan-
dardize the step towards systemic therapy.
New therapies are developed and approved rapidly, and as
a consequence regular updates of guidelines are required.
The process of writing a guideline is precise, time consum-
ing and as a result also expensive. To improve the efficiency
in guideline development and to lower the burden of data
analysis, we worked together with the EDF guideline work-
ing group, and shared our literature searches and GRADE
analysis back and forth. Although treatment recommenda-
tions can differ between countries because of local regula-
tions, availability of medicines, cooperation with other
medical specialists and healthcare costs, the quality assess-
ment of the literature should be uniform. We propose that
further collaboration between guideline developers on quality
assessment could limit the workload and that sharing of
knowledge and expertise might also increase the overall
quality of the guidelines.
Currently, we are discussing a collaboration between the
Cochrane Skin Group, network systematic review groups, the
EDF and national guideline development groups. We expect
that in this way we will be able to create living guidelines,
which will be updated frequently and therefore will remain
up to date.
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